ID
26549
Beskrivning
Study ID: 101468/168 Clinical Study ID: 101468/168 Study Title: A Randomised, Double Blind, Three Period, Cross-Over Study of Ropinirole CR and Ropinirole IR Monotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara Study Indication: Parkinson Disease
Nyckelord
Versioner (1)
- 2017-10-18 2017-10-18 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
18 oktober 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Serious adverse events Ropinirole CR Ropinirole IR Monotherapy 101468/168
Serious adverse events Ropinirole CR Ropinirole IR Monotherapy 101468/168
Beskrivning
SERIOUS ADVERSE EVENT (SAE)
Beskrivning
SECTION 1: Serious adverse event
Beskrivning
Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE however if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page.
Datatyp
text
Beskrivning
Record the start date of the first occurrence of the SAE.
Datatyp
date
Alias
- UMLS CUI [1]
- C0808070
Beskrivning
All SAEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the SAE was ongoing at the time of death, but was not the cause of death, enter fatal for the SAE which was the direct cause of death.
Datatyp
integer
Beskrivning
Record the end date. This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died. If the event Recovered/Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the SAE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.
Datatyp
date
Alias
- UMLS CUI [1]
- C0806020
Beskrivning
Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases. Mild= An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate=An event that is sufficiently discomforting to interfere with normal everyday activities. Severe= An event that prevents normal everyday activities. Not applicable=those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).
Datatyp
text
Beskrivning
Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was temporarily interrupted but then restarted. Not applicable =Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing) or the subject died and there was no prior decision to discontinue IP(s).
Datatyp
text
Beskrivning
Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’.
Datatyp
text
Beskrivning
It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.
Datatyp
text
Beskrivning
SECTION 2: Seriousness
Beskrivning
SAE results in death
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0011065
Beskrivning
Note: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C2826244
Beskrivning
Note: In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or out-patient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is ’serious’. When in doubt as to whether ’hospitalisation’ occurred or was necessary, the AE should be considered ’serious’. Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0019993
Beskrivning
Note: The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0231170
Beskrivning
Congenital anomaly/birth defect
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0000768
Beskrivning
Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse.
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C1880177
Beskrivning
Other SAE specification
Datatyp
text
Alias
- UMLS CUI [1]
- C3845569
Beskrivning
Insert study specific item
Datatyp
boolean
Beskrivning
SECTION 3: Demography data
Beskrivning
SECTION 4: Recurrence of SAE
Beskrivning
If deliberate or inadvertant administration of further dose(s) of investigational product(s) to the subject occurred, did the reported adverse event recur?
Datatyp
text
Beskrivning
SECTION 5: Possible Causes of SAE Other Than Investigational Product(s)
Beskrivning
Disease under study
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0012634
Beskrivning
(record in Section 6)
Datatyp
boolean
Alias
- UMLS CUI [1]
- C1699700
Beskrivning
Lack of efficacy
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0235828
Beskrivning
Withdrawal of investigational product
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C2349954
- UMLS CUI [1,2]
- C0013227
Beskrivning
Concomitant Medication
Datatyp
boolean
Alias
- UMLS CUI [1]
- C2347852
Beskrivning
Activity related to study participation
Datatyp
boolean
Alias
- UMLS CUI [1]
- C2348568
Beskrivning
Other possible Cause of SAE
Datatyp
boolean
Beskrivning
Other possible Cause of SAE specification
Datatyp
text
Beskrivning
SECTION 6: RELEVANT Medical Conditions
Beskrivning
Relevant Medical Conditions
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0012634
- UMLS CUI [1,2]
- C0262926
- UMLS CUI [1,3]
- C1519255
Beskrivning
Date of onset
Datatyp
date
Alias
- UMLS CUI [1]
- C0574845
Beskrivning
Condition Present at Time of the SAE
Datatyp
text
Beskrivning
Date of Last Occurrence
Datatyp
date
Beskrivning
SECTION 7: Other RELEVANT Risk Factors
Beskrivning
SECTION 8: RELEVANT Concomitant Medications
Beskrivning
(Trade name preferred)
Datatyp
text
Alias
- UMLS CUI [1]
- C0013227
Beskrivning
Dose
Datatyp
float
Alias
- UMLS CUI [1]
- C3174092
Beskrivning
Unit
Datatyp
text
Beskrivning
Frequency
Datatyp
text
Beskrivning
Route
Datatyp
text
Alias
- UMLS CUI [1]
- C0013153
Beskrivning
administration prior to study
Datatyp
text
Beskrivning
Start Date
Datatyp
date
Alias
- UMLS CUI [1]
- C0808070
Beskrivning
Stop Date
Datatyp
date
Alias
- UMLS CUI [1]
- C0806020
Beskrivning
Ongoing Medication
Datatyp
text
Alias
- UMLS CUI [1]
- C2826666
Beskrivning
Reason for Medication
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0392360
- UMLS CUI [1,2]
- C0013227
Beskrivning
SECTION 9: Details of Investigational Product(s)
Beskrivning
SECTION 10: Details of RELEVANT Assessments
Beskrivning
SECTION 11: Narrative Remarks
Beskrivning
Investigator information
Beskrivning
Confirming that the data on the SAE pages are accurate and complete.
Datatyp
text
Alias
- UMLS CUI [1]
- C2346576
Beskrivning
Investigator name
Datatyp
text
Alias
- UMLS CUI [1]
- C2826892
Beskrivning
Investigator Signature Date
Datatyp
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Similar models
Serious adverse events Ropinirole CR Ropinirole IR Monotherapy 101468/168
C0678257 (UMLS CUI [1,2])
C1880177 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
C0262926 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])